Phathom Pharmaceuticals IncNASDAQ:PHAT
- LAST PRICE9.9250
- TODAY'S CHANGE (%)-0.8850 (-8.1869%)
- Bid / Lots9.8800/ 1
- Ask / Lots9.9700/ 4
- Open / Previous Close10.8100 / 10.8100
- Day Range
- 52 Week Range
- Volume211,383
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PHAT |
|---|---|---|
| 09:32 ET | 6569 | 10.41 |
| 09:38 ET | 1420 | 10.55 |
| 09:39 ET | 1200 | 10.59 |
| 09:41 ET | 100 | 10.6735 |
| 09:45 ET | 786 | 10.57 |
| 09:48 ET | 1255 | 10.52 |
| 09:50 ET | 3200 | 10.57 |
| 09:52 ET | 605 | 10.57 |
| 09:54 ET | 300 | 10.53 |
| 09:56 ET | 1380 | 10.64 |
| 09:57 ET | 2234 | 10.615 |
| 09:59 ET | 6311 | 10.66 |
| 10:01 ET | 435 | 10.67 |
| 10:03 ET | 11524 | 10.68 |
| 10:06 ET | 2535 | 10.63 |
| 10:08 ET | 2001 | 10.62 |
| 10:10 ET | 678 | 10.69 |
| 10:14 ET | 447 | 10.69 |
| 10:15 ET | 3125 | 10.66 |
| 10:17 ET | 200 | 10.66 |
| 10:19 ET | 717 | 10.66 |
| 10:21 ET | 1491 | 10.64 |
| 10:24 ET | 640 | 10.635 |
| 10:26 ET | 2008 | 10.54 |
| 10:28 ET | 300 | 10.5559 |
| 10:30 ET | 1632 | 10.57 |
| 10:32 ET | 864 | 10.5756 |
| 10:33 ET | 100 | 10.6 |
| 10:46 ET | 400 | 10.59 |
| 10:48 ET | 200 | 10.61 |
| 10:50 ET | 100 | 10.61 |
| 10:51 ET | 400 | 10.595 |
| 10:57 ET | 2000 | 10.57 |
| 11:00 ET | 427 | 10.58 |
| 11:02 ET | 100 | 10.6 |
| 11:06 ET | 890 | 10.62 |
| 11:09 ET | 314 | 10.6 |
| 11:11 ET | 400 | 10.61 |
| 11:15 ET | 500 | 10.61 |
| 11:18 ET | 514 | 10.61 |
| 11:20 ET | 200 | 10.63 |
| 11:22 ET | 500 | 10.63 |
| 11:26 ET | 285 | 10.63 |
| 11:27 ET | 1778 | 10.64 |
| 11:31 ET | 100 | 10.68 |
| 11:33 ET | 200 | 10.69 |
| 11:36 ET | 9089 | 10.71 |
| 11:38 ET | 200 | 10.69 |
| 11:40 ET | 200 | 10.69 |
| 11:42 ET | 552 | 10.71 |
| 11:44 ET | 200 | 10.725 |
| 11:45 ET | 4932 | 10.65 |
| 11:47 ET | 5987 | 10.59 |
| 11:51 ET | 100 | 10.59 |
| 12:00 ET | 200 | 10.56 |
| 12:02 ET | 840 | 10.55 |
| 12:03 ET | 1645 | 10.56 |
| 12:05 ET | 7130 | 10.605 |
| 12:07 ET | 200 | 10.615 |
| 12:12 ET | 100 | 10.6 |
| 12:16 ET | 100 | 10.582 |
| 12:18 ET | 200 | 10.55 |
| 12:20 ET | 100 | 10.52 |
| 12:21 ET | 500 | 10.54 |
| 12:27 ET | 100 | 10.51 |
| 12:32 ET | 100 | 10.45 |
| 12:34 ET | 2006 | 10.43 |
| 12:36 ET | 100 | 10.44 |
| 12:38 ET | 3197 | 10.39 |
| 12:39 ET | 9151 | 10.41 |
| 12:41 ET | 2227 | 10.3574 |
| 12:43 ET | 8423 | 10.31 |
| 12:45 ET | 4489 | 10.22 |
| 12:48 ET | 5932 | 10.165 |
| 12:50 ET | 18674 | 10.03 |
| 12:52 ET | 21140 | 9.875 |
| 12:54 ET | 4103 | 9.925 |
Jun 28, 2024
DJ Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by Needham, from 11:12AM ET on Friday Jun 28, 2024 by Dow Jones
11:12AM ET on Friday Jun 28, 2024 by Dow Jones
Jun 21, 2024
DJ Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by Needham, from 10:15AM ET on Friday Jun 21, 2024 by Dow Jones
10:15AM ET on Friday Jun 21, 2024 by Dow Jones
Jun 14, 2024
DJ Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by Needham, from 8:54AM ET on Friday Jun 14, 2024 by Dow Jones
8:54AM ET on Friday Jun 14, 2024 by Dow Jones
Jun 7, 2024
DJ Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by Needham, from 8:36AM ET on Friday Jun 07, 2024 by Dow Jones
8:36AM ET on Friday Jun 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Phathom Pharmaceuticals Inc | 632.8M | -2.2x | --- |
Replimune Group Inc | 627.9M | -2.6x | --- |
Humacyte Inc | 639.5M | -5.1x | --- |
Savara Inc | 641.2M | -11.7x | --- |
Olema Pharmaceuticals Inc | 623.1M | -5.1x | --- |
Scholar Rock Holding Corp | 648.4M | -3.7x | --- |
Company Information
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Contact Information
- Headquarters
- 100 Campus Drive, Suite 102FLORHAM PARK, NJ, United States 07932
- Phone
- 302-636-5400
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Michael Cola
- Director
- Terrie Curran
- Co-Founder, Chief Operating Officer
- Azmi Nabulsi
- Co-Founder, Director
- David Socks
- Chief Financial Officer and Business Officer
- Molly Henderson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $632.8M |
|---|---|
Revenue (TTM) | $2.6M |
Shares Outstanding | 58.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.68 |
EPS | $-4.41 |
Book Value | $-1.26 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | 243.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -7,987.24% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
